Rockwell Medical (FRA:RWM) Risk Assessment


FRA:RWM Rockwell Medical Inc FRA:RWM
30 GF Score
Price €5.25
GF Value €0.90
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Rockwell Medical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Rockwell Medical is: High Risk: High uncertainty with risk-return tradeoff.

Rockwell Medical  (FRA:RWM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Rockwell Medical Risk Assessment Related Terms

FRA:RWM vs CPHI, TXMD, MRMD: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rockwell Medical Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Rockwell Medical's Risk Assessment falls into.


FRA:RWM
30GF Score
Rockwell Medical Inc FRA:RWM
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rockwell Medical (FRA:RWM) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be overvalued. The current stock price of €5.25 is trading 483.3% above its estimated GF Value™ of €0.90. GuruFocus considers Rockwell Medical to be Significantly Overvalued.

Key valuation signals for FRA:RWM:

  • Risk Assessment:
  • GF Value™: €0.90 vs. price of €5.25 (483.3% above fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rockwell Medical Business Description

Other Exchanges RMTI:USA
Address 30142 South Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
30GF Score

Get the complete analysis for FRA:RWM

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price
€0.90
GF Value